TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01164046

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low molecular weight heparin
Description: weight adjusted dose of low molecular weight heparin, any type allowed if approved, 65-75% of full therapeutic dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin K antagonists
Description: Target INR between 2-3. Any type allowed, if approved for use in that country.
Study: NCT00061048

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Infusion of Campath-1H 3 mg on day # 1, 10 mg on day #2, and 30 mg day # 3 followed by maintenance Campath-1H 30 mg intravenously three times per week. Patients are eligible to receive a maximum of 12 weeks of maintenance Campath-1H treatment.
Study: NCT06154434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorpromazine HCl 100mg Tablets
Description: single-dose administered after a 10-hour overnight fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorpromazine HCl 100mg Tablets
Description: single-dose administered after a 10-hour overnight fast.
Study: NCT00546143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Study: NCT03059940

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quitline
Description: Participants referred to the Quitline for counseling. Participants have 5 smoking cessation counseling sessions over the next 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quitline
Description: Participants referred to the Quitline for counseling. Participants have 5 smoking cessation counseling sessions over the next 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy Discussion
Description: Participant informed of the risk, benefits and relative efficacy of cessation medications and to assess their medication preferences, expectations and medical suitability for either option. At the conclusion of this conversation the patient is provided with an initial supply of the medication jointly decided between provider and patient.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy Discussion
Description: Participant informed of the risk, benefits and relative efficacy of cessation medications and to assess their medication preferences, expectations and medical suitability for either option. At the conclusion of this conversation the patient is provided with an initial supply of the medication jointly decided between provider and patient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: Nicotine patch dispensed. Dosing at physician's discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Smoking Drug
Description: Varenicline or Buproprion prescribed by study doctor with directions of when and how much of anti-smoking drug that should be taken each time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Smoking Drug
Description: Varenicline or Buproprion prescribed by study doctor with directions of when and how much of anti-smoking drug that should be taken each time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Treatment Program
Description: Participant referred to Tobacco Treatment Program (TTP). TTP provides 4-8 counseling sessions and pharmacotherapy over a 10-12 week period,

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbon Monoxide (CO) Level Test
Description: Participant asked to blow air through a CO-measuring device.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbon Monoxide (CO) Level Test
Description: Participant asked to blow air through a CO-measuring device.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbon Monoxide (CO) Level Test
Description: Participant asked to blow air through a CO-measuring device.
Study: NCT00546143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Study: NCT03243734

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: trūFreeze® System spray cryotherapy
Description: Subjects where trūFreeze® System spray cryotherapy is performed
Study: NCT03361410

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Grape Powder
Description: 36 g of grape powder to be taken twice/day (total of 72 g/day) for 12 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Powder
Description: 36 g of placebo powder to be taken twice/day (total of 72 g/day) for 12 months
Study: NCT01379092

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trident Specimen Radiography System
Description: MIBB images will be acquired on the standard of care device and the Trident System in the Breast Center at Hoag Hospital. BSS images will be acquired on standard of care device in the Operating Room and/or the Breast Center at Hoag Hospital and then on the Trident System. Image quality will be compared and system operation will be evaluated. Feedback will be provided to manufacturer and the Trident System further refined.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioptics, Faxitron, and Full Field Digital Mammography (FFDM) Selenia
Description: All the above devices are used for SOC BSS imaging at Hoag Hospital. The images captured from these devices will be compared to the images captured from the Trident Specimen Radiography device.
Study: NCT00885872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (Crestor)
Description: at visit 2 each eligible subject will be allocated to rosuvastatin. study medication wil be taken orally with water once daily, as directed by the study physician. subjects who meet the criteria at visit 3, dosage of rosuvastatin will be titrated.
Study: NCT02629406

Intervention type: OTHER
Intervention: Hypoxia
Description: Intermittent hypoxia which consist of five hypoxic periods (13% O2 inspired fraction of oxygen) each lasting 6 min, with five normoxic intervals of same duration

Intervention type: OTHER
Intervention: Hypoxia
Description: Intermittent hypoxia which consist of five hypoxic periods (13% O2 inspired fraction of oxygen) each lasting 6 min, with five normoxic intervals of same duration
Study: NCT03766321

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fecal microbiota transplantation
Description: Fecal microbiota transplantation will be performed during two endoscopic procedures (baseline and at 6 months) by allogenic infusion of collected feces in the duodenum-jejunum.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients will undergo endoscopic procedure with biopsy during sedation but without any kind of intervention
Study: NCT01915563

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: REST
Description: After a SBT patients will be extubated as usual or reconnected to mechanical ventilation for 60 min before extubation.
Study: NCT01231763

Intervention type: OTHER
Intervention: No intervention (not applicable)
Description: No intervention (not applicable)
Study: NCT02710526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAM2038
Description: Long-Acting Subcutaneous Injectable Depot of Buprenorphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAM2038
Description: Long-Acting Subcutaneous Injectable Depot of Buprenorphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAM2038
Description: Long-Acting Subcutaneous Injectable Depot of Buprenorphine
Study: NCT02109588

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A supervised physical exercise program
Description: Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60% of heart rate reserve. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate
Study: NCT03050931

Intervention type: DEVICE
Intervention: Electrical Impedance Tomography
Description: EIT comprises of a box of electronics similar in size to a video recorder, laptop computer and leads which link typically to 16 or 32 external ECG-like electrodes placed around the subject. Images are generated by applying tiny electrical signals through some electrodes and recording the resulting signals at others. The signals applied are completely safe, within established British and EU safety limits and cannot be felt. For intracranial electrode studies, the EIT systems will be linked to the existing EEG video recording systems and EIT will be recorded at the same time using some or all of the available intracranial electrodes.
Study: NCT01524640

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Killed Bivalent (O1 and O139) whole cell oral cholera vaccine
Description: 1.5 ml single dose oral administration on day 0 and day 14

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1.5 ml oral administration on day 0 and day 14
Study: NCT00620230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-VAK694
Study: NCT01903447

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SSRI

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Study: NCT01451294

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Administration of phenylephrine
Description: Phenylephrine: 50-100µg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Administration of ephedrine
Description: Ephedrine: 5- 10 mg
Study: NCT00951210

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PLX-PAD
Description: IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PLX-PAD
Description: IM injection
Study: NCT00139997

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Litebook treatment devices
Description: Litebook LED phototherapy device used for 30 min before 8 am

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Inactivated negative ion generator
Description: Equivalent exposure to inactivated negative ion generator
Study: NCT01632579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3023703
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Administered orally
Study: NCT00162136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Intravenous (IV) Infusion; 10, 20, 30, 35, 40 \& 45 mg/m2, once every 21 days (1 cycle), up to 9 cycles
Study: NCT03481946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1093884
Description: 0.3 mg/kg given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1093884
Description: 1 mg/kg given intravenously
Study: NCT03156231

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACETAZOLAMIDE oral capsule
Description: Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
Study: NCT02286882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06409577 or Placebo
Description: PF-06409577or placebo will be administered as an extemporaneously prepared suspension once in each cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06409577 or Placebo
Description: PF-06409577or placebo will be administered as an extemporaneously prepared suspension once in each cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06409577 or Placebo
Description: PF-06409577or placebo will be administered as an extemporaneously prepared suspension once in each cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06409577 or Placebo
Description: PF-06409577or placebo will be administered as an extemporaneously prepared suspension once in each cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06409577 or Placebo
Description: PF-06409577or placebo will be administered as an extemporaneously prepared suspension once in each cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06409577 or Placebo
Description: PF-06409577or placebo will be administered as an extemporaneously prepared suspension once in each cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06409577 or Placebo
Description: PF-06409577or placebo will be administered as an extemporaneously prepared suspension once in each cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06409577 or Placebo
Description: PF-06409577or placebo will be administered as an extemporaneously prepared suspension once in each cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06409577 or Placebo
Description: PF-06409577or placebo will be administered as an extemporaneously prepared suspension once in each cohort
Study: NCT05060224

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EasyLaser: Low Level Laser therapy
Study: NCT05491629

Intervention type: OTHER
Intervention: type of parallel data in a convergent parallel hash pattern (near time)
Description: The quantitative part of the study is a descriptive study with the Perceived Perioperative Competence Scale-Revised to determine the perceptions of operating room nurses about their competencies.~It is a case study in order to reveal the opinions of the surgical team members about the competencies of the operating room nurses and the affecting factors through individual in-depth interviews and to better explain the current situation at the qualitative stage, which is carried out simultaneously.
Study: NCT01693601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: PO TIW QOW or PO TIW QW

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: PO BID x 28 days
Study: NCT01587183

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Educational material control
Description: Participants will be given educational materials on starting a running program using a run/walk approach.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group running style B
Description: Participants will attend a 4 hour group based training and 3, 2 hour follow up trainings.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group running style A
Description: Participants will attend a 4 hour group based training and 3, 2 hour follow up trainings.
Study: NCT00818441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib (PF-00299804)
Description: Dacomitinib (PF-00299804) at 45 mg daily or 30 mg daily by continuous oral dosing, to be escalated in tolerating patients to 45mg after at least 8 weeks of therapy (30 patients in Cohort A started at the lower dose).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib (PF-00299804)
Description: In Cohort B, patients getting Dacomitinib for first line therapy started at 30 mg, but those who had prior anti-cancer therapy started at 45 mg.
Study: NCT03856229

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional steroid regimen
Description: Subjects will receive the conventional steroid regimen with prednisolone or equivalent (with methylprednisolone): Day 1 to 5: 40 mg orally every 12 h; Day 6 to 10: 40 orally every 24 hours; and Day 11 to 21: 20 mg orally every 24 h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shortened steroid regimen
Description: * Subjects with Moderate PCP. Prednisolone (or equivalent with methylprednisolone) 40 mg orally every 12 h (Day 1 to 5);40 mg orally every 24 hours (Day 6 to 8).~* Subjects with severe PCP. Prednisolone (or equivalent with methylprednisolone) 40 mg orally every 12 h (Day 1 to 5),40 mg orally every 24 hours (Day 6 to 10); and 20 mg orally every 24 h (Day 11 to 14).
Study: NCT03966235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg
Description: Melatonin was taken daily for 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet was taken daily for 6 months.
Study: NCT06535204

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aqueous extract of A. sylvestris leaves
Description: Provided functional food made from Aqueous extract of A. sylvestris leaves

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: microcrystalline cellulose
Description: Provided placebo composed of microcrystalline cellulose instead of A. sylvestris leaf extract.
Study: NCT02490813

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Treatment - Chinese Herbal Formula - X
Description: Wu Mei (Fructus Pruni Mume), Ling Zhi (Gonoderma), Huang Bai (Cortex Phellodendron), and Zhi Su (Perilla frutescens).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be starch with colorings
Study: NCT03213093

Intervention type: OTHER
Group type: OTHER
Intervention: Measure of cutaneous microcirculation
Description: Measure of cutaneous microcirculation in response to a local application of pressure, to local heating and to the iontophoretic administration of acetylcholine
Study: NCT02376413

Intervention type: PROCEDURE
Intervention: Breast surgery
Description: Traditional breast-conserving surgery, oncoplastic breast-conserving surgery or modified radical mastectomy

Intervention type: PROCEDURE
Intervention: Breast surgery
Description: Traditional breast-conserving surgery, oncoplastic breast-conserving surgery or modified radical mastectomy

Intervention type: DRUG
Intervention: Chemotherapy or endocrine therapy or Trastuzumab therapy

Intervention type: DRUG
Intervention: Chemotherapy or endocrine therapy or Trastuzumab therapy

Intervention type: RADIATION
Intervention: Radiation therapy

Intervention type: RADIATION
Intervention: Radiation therapy
Study: NCT00950638

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARC1905
Description: intravitreal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARC1905
Description: intravitreal injection
Study: NCT02972099

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TcPRF
Description: Transcutaneous Pulsed Radiofrequency is a method that is widely used for control of pain. There are no known complications. In this study a Radiofrequency generator will be used that has a separate outlet for transcutaneous use. It is used in the daily clinical practice in the Pain Center of the Swiss Paraplegic Center.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In the Placebo Treatment, no current will be delivered. Since no sensations are produced by TcPRF treatment the patients won't recognize the difference.
Study: NCT03857438

Intervention type: DRUG
Intervention: Ongoing treatment for bipolar mania
Description: Prescribed by the following doctor during hospitalization and after discharge

Intervention type: DIAGNOSTIC_TEST
Intervention: Audiovisual recording during guided presentation
Description: Seven tasks such as explaining the reason to come to hospital/participate in the activity, describing happy and sad memories, counting up to thirty, explaining two emotion eliciting pictures

Intervention type: DIAGNOSTIC_TEST
Intervention: Audiovisual recording during guided presentation
Description: Seven tasks such as explaining the reason to come to hospital/participate in the activity, describing happy and sad memories, counting up to thirty, explaining two emotion eliciting pictures
Study: NCT04604522

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood, airway brushings.

Intervention type: OTHER
Intervention: Medical Chart Review
Description: Patients' medical records are reviewed
Study: NCT01612546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclodextrin-based polymer-camptothecin CRLX101
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological studies
Description: Correlative studies
Study: NCT03861000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [C-11]T-1650
Description: radio-labeled drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [C-11]T-1650
Description: radio-labeled drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPN14770
Description: selective compound
Study: NCT01688336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: FOLFIRINOX will be given intravenously on Days 1, 15, and 28 of each 28 day cycle. Drugs are given in combination in this order:~* Oxaliplatin (85 mg/m2)~* Leucovorin (400mg/ m2)~* Irinotecan (180 mg/m2)~* 5FU (400mg/m2)bolus then 2400 mg/m2 over 46 hours
Study: NCT03208972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose hCG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hp-FSH
Study: NCT03548454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Open label prescription

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desipramine
Description: Open label prescription
Study: NCT03911466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine Injection
Description: Weekly and monthly formulations of injectable, extended-release buprenorphine (BUP-XR).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine Sublingual Product
Description: Sublingual buprenorphine (BUP-SL), administered daily.
Study: NCT03208972

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corifollitropin Alfa
Description: Corifollitropin Alfa (Elonva) dosage depending on weight, once administered first day of ovarian stimulation for all subjects, and on day 7 they proceed with the treatment of the allocated group.~\<60 kg: Elonva 100 MCG \> 60 kg: Elonva 150 MCG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corifollitropin Alfa
Description: Corifollitropin Alfa (Elonva) dosage depending on weight, once administered first day of ovarian stimulation for all subjects, and on day 7 they proceed with the treatment of the allocated group.~\<60 kg: Elonva 100 MCG \> 60 kg: Elonva 150 MCG
Study: NCT03313362

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPEAC System
Description: Seizure Monitoring and Alerting System

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: video EEG
Description: The Video EEG Monitoring Test (VEEG) is a high specialized form of an EEG test in where the patient is continuosly monitored by using a video recorder. This allows doctors to observe brainwaves activity during the time a seizure or spell is occurring.